Metropolis Healthcare Limited
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinic… Read more
Metropolis Healthcare Limited - Asset Resilience Ratio
Metropolis Healthcare Limited (METROPOLIS) has an Asset Resilience Ratio of 4.49% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Metropolis Healthcare Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Metropolis Healthcare Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹600.86 Million | 3.02% |
| Short-term Investments | ₹294.13 Million | 1.48% |
| Total Liquid Assets | ₹894.99 Million | 4.49% |
Asset Resilience Insights
- Limited Liquidity: Metropolis Healthcare Limited maintains only 4.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Metropolis Healthcare Limited Industry Peers by Asset Resilience Ratio
Compare Metropolis Healthcare Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Metropolis Healthcare Limited (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Metropolis Healthcare Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 4.38% | ₹817.54 Million | ₹18.67 Billion | +0.58pp |
| 2024-03-31 | 3.80% | ₹590.32 Million | ₹15.55 Billion | -0.96pp |
| 2023-03-31 | 4.75% | ₹713.61 Million | ₹15.02 Billion | -3.99pp |
| 2022-03-31 | 8.74% | ₹1.34 Billion | ₹15.30 Billion | -23.09pp |
| 2021-03-31 | 31.83% | ₹3.20 Billion | ₹10.04 Billion | +17.93pp |
| 2020-03-31 | 13.90% | ₹1.05 Billion | ₹7.52 Billion | +5.23pp |
| 2019-03-31 | 8.67% | ₹479.07 Million | ₹5.53 Billion | -11.82pp |
| 2018-03-31 | 20.49% | ₹1.09 Billion | ₹5.30 Billion | -8.20pp |
| 2017-03-31 | 28.69% | ₹1.48 Billion | ₹5.15 Billion | +3.19pp |
| 2016-03-31 | 25.50% | ₹1.01 Billion | ₹3.96 Billion | -10.44pp |
| 2015-03-31 | 35.94% | ₹1.67 Billion | ₹4.64 Billion | +2.68pp |
| 2014-03-31 | 33.26% | ₹1.31 Billion | ₹3.93 Billion | -- |